[외부감사 진단] HLB 자산 50% 보유 엘레바…명운 건 FDA 승인

The outcome of FDA approval for HLB's core pipelines represents a critical financial junction where research success directly dictates the company's valuation and asset integrity. A failure in the upcoming clinical milestones could trigger massive impairment losses, highlighting the high-risk, high-reward nature of the biotech industry's asset management. This case underscores how regulatory hurdles serve as the ultimate validator for R&D-heavy corporate structures.